About the Cover
The immunofluorescence image depicts DNA double strand breaks (DSBs) occurring in S phase, a critical genetic event where BRCA2 plays a crucial role in homologous recombination. The colon cancer cell line HT-29 was exposed to SN-38, a topoisomerase-1 inhibitor and treated with bromodeoxyuridine (BrdU). Two-color immunofluorescence staining using anti-BrdU and anti-53BP1 antibodies showed S-phase cell nuclei and the cytoplasm stained in red, together with the DSB nuclear foci detected by anti-53BP1 staining. Credit: M Tahara & K Sugano, Tochigi Cancer Center Research Institute, Tochigi, Japan
Most
-
Viewed
- Progesterone metabolites in breast cancer
- Association of Hashimoto's thyroiditis with thyroid cancer
- The emerging roles of DNA methylation in the clinical management of prostate cancer
- Lipomatous tumours in adrenal gland: WHO updates and clinical implications
- Design and validation of specific inhibitors of 17{beta}-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis
-
Cited
- Fibroblast growth factors, their receptors and signaling
- The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification
- BRAF mutation in thyroid cancer
- mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer
- Diabetes and cancer
